MetaVia (NASDAQ:MTVA) Releases Earnings Results, Misses Estimates By $0.03 EPS
by Doug Wharley · The Cerbat GemMetaVia (NASDAQ:MTVA – Get Free Report) posted its earnings results on Thursday. The company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.03), Zacks reports.
MetaVia Stock Performance
Shares of NASDAQ MTVA traded down $0.01 during midday trading on Thursday, reaching $1.19. The stock had a trading volume of 64,112 shares, compared to its average volume of 148,932. MetaVia has a 12-month low of $0.97 and a 12-month high of $19.03. The stock has a 50-day moving average of $1.40 and a 200-day moving average of $4.58. The company has a market capitalization of $6.14 million, a price-to-earnings ratio of -0.14 and a beta of 0.59.
Wall Street Analyst Weigh In
Several analysts have commented on the stock. HC Wainwright lowered their price objective on shares of MetaVia from $40.00 to $20.00 and set a “buy” rating on the stock in a research report on Friday, March 27th. Wall Street Zen raised shares of MetaVia from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of MetaVia in a research report on Friday, April 24th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $26.50.
Read Our Latest Research Report on MTVA
Institutional Trading of MetaVia
A hedge fund recently bought a new stake in MetaVia stock. Virtu Financial LLC bought a new stake in shares of MetaVia Inc. (NASDAQ:MTVA – Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned approximately 0.14% of MetaVia as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 1.37% of the company’s stock.
About MetaVia
MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.